EUVIMEDEUVIMED entdecken
FallberichtKlinische StudieOpen Access · CC BY-NC 3.0

Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial

Jason Bacharach, Iqbal Ike K Ahmed, Elizabeth D Sharpe, Michael S Korenfeld iD, Steven Zhang, Christophe Baudouin iD

Clinical Ophthalmology · 2023-09 · Volume 17 · 2575-2588

DOI: 10.2147/opth.s414015 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Ophthalmology, 2023-09. Verfasst von Jason Bacharach und 5 weiteren Autor:innen. Beteiligte Einrichtung: North Bay Eye Associates, Sonoma County, CA, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the safety and efficacy of a preservative-free latanoprost 0.005% formulation (T2345) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) compared to benzalkonium chloride-preserved latanoprost 0.005% (BPL) formulation in the United States (US). Patients and Methods: A prospective, randomized, multicenter, observer-masked, parallel-group study enrolled 335 patients diagnosed with POAG or OHT from 31 US sites who had adequately controlled intraocular pressure (IOP; ≤18 mm Hg) with latanoprost monotherapy. After a ≥72-hour washout period, patients were randomized to T2345 (n=165) or BPL (n=170) groups. Study drugs were dosed once-daily from Day 0 to Day 84 in one or both eyes. The study eye was the eye with lower IOP at baseline. The primary efficacy measure was the between-group comparison of the mean IOP values in the study eye at each time point (8 AM, 10 AM, and 4 PM on Days 15, 42, and 84). Safety measurements included ocular and systemic treatment-emergent adverse events (TEAEs).

Results

Both T2345 and BPL adequately controlled IOP with 95% CIs within 1.5 mm Hg in the study eye at all assessed time points. The percentages of patients with diurnal IOP

Schlagwörter

Stichwörter der Autor:innen

benzalkonium chlorideglaucomaintraocular pressurelatanoprostocular hypertensionpreservative

Autor:innen und Institutionen

  • North Bay Eye Associates, Sonoma County, CA, USA.
  • John Moran Eye Center, University of Utah, Salt Lake City, UT, USA.
  • Glaucoma Consultants and Center for Eye Research, Mt. Pleasant, SC, USA.
  • Comprehensive Eye Care, Washington, MO, USA.
  • Thea Pharma, Inc, Lexington, MA, USA.
  • Quinze-Vingts National Ophthalmology Hospital & Vision Institute, Paris Saclay-Versailles-Saint Quentin University, IHU Foresight, Paris, France.

ORCID-Profile: Michael S Korenfeld, Christophe Baudouin

Zitieren

APA

Bacharach, J., Ahmed, I. I. K., Sharpe, E. D., Korenfeld, M. S., Zhang, S., & Baudouin, C. (2023). Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial. Clinical Ophthalmology, Volume 17, 2575-2588. https://doi.org/10.2147/opth.s414015

Vancouver

Bacharach J, Ahmed IIK, Sharpe ED, Korenfeld MS, Zhang S, Baudouin C. Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial. Clinical Ophthalmology. 2023;Volume 17:2575-2588. doi:10.2147/opth.s414015

BibTeX
@article{Bacharach2023,
  author = {Bacharach, Jason and Ahmed, Iqbal Ike K and Sharpe, Elizabeth D and Korenfeld, Michael S and Zhang, Steven and Baudouin, Christophe},
  title = {Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial},
  journal = {Clinical Ophthalmology},
  year = {2023},
  volume = {Volume 17},
  pages = {2575--2588},
  doi = {10.2147/opth.s414015}
}
Kostenlos starten →